-
Mancini finds positives in Italy loss, accepts fans' jeers
-
Mbappe injured as Zidane wins on France debut, Italy lose on Mancini return
-
Alcaraz helps Europe into Laver Cup lead
-
Senegal draw in Vieira debut, Nigeria survive scare as Cape Verde crash
-
Six missing after building collapses in historic Athens district
-
U2 performs surprise 50th anniversary gigs in Dublin
-
Mbappe scores but suffers knee injury as Zidane gets debut France win
-
Pope calls worshippers 'saints of France' after AI warning
-
Mancini's Italy return spoiled by Belgium defeat
-
US court sides with Pentagon in Anthropic AI ban
-
Rodri confident in Man City innocence despite reported charges
-
Wall Street stocks rise, greeting optimism over possible US-Iran deal
-
Jay-Z rape accuser says she made 'false accusations'
-
NFL players chief raises concerns over pitch for Maracana game
-
Senegal draw first match under Vieira and Nigeria survive scare
-
Daytime Russian attacks kill seven in Kyiv
-
Trump, Xi end summit long on pomp, but short on progress
-
Spotting AI writing: how reliable are the detectors?
-
Russia not preparing for conflict with Europe, Putin says
-
French youth await pope after AI 'paradise of machines' warning
-
Trump's photo of Xi greeting carries signs of AI
-
Man City found guilty of Premier League charges, set to appeal: reports
-
Six missing after building blast in historic Athens district
-
Embolo follows Xhaka out of Swiss squad over fake Covid documents
-
Millions in US northeast brace for powerful storm
-
Trump, Xi inspect founding documents of US democracy to close summit
-
Assefa seeks 'better than my best' at Berlin marathon
-
'Bottle Claus': Kipchoge's 'hero' helping runners chase Berlin marathon glory
-
US court refuses to overturn Pentagon ban on Anthropic
-
Olympic medallist Samba-Mayela handed provisional doping ban
-
Verstappen and Norris blame slow cars as Mercedes tops qualifying
-
First US trial against TikTok to open Monday
-
Crowds cheer pope in Paris after AI 'paradise of machines' warning
-
Palmer misses 'too many' England games, says Tuchel
-
Teen swimmer makes Games history as Thai, Chinese sprinters win gold
-
UN refugees chief warns conditions in W.Sahara 'deteriorating'
-
Man City found guilty of 114 Premier League charges - reports
-
Antonelli 'mad' about crash in Azerbaijan qualifying
-
Concerns over 'missing' UK explorer Ranulph Fiennes
-
'Perfect lap' gives Russell pole for Azerbaijan GP as Antonelli crashes out
-
Suspected Paris killer of Argentine rugby star begs forgiveness
-
UN Security Council condemns Houthi attacks on Saudi Arabia
-
Oil prices fall on cautious hopes for US-Iran progress
-
China swimmer makes Asian Games history as Thai wins 100m sprint
-
Noskova, Muchova take Czech Republic into BJK Cup final
-
Top French literary prize drops best-selling novel over AI claims
-
Thai sprinter Puripol breaks own Asian Games record to win 100m gold
-
US 'must choose' whether to end war: Iran president
-
Russell takes pole for Azerbaijan GP, Antonelli crashes out
-
Pope warns against losing humanity in AI-driven 'paradise of machines'
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
A.Ammann--VB